Molecular Partners AG (MOLN)
NASDAQ: MOLN · Real-Time Price · USD
5.20
-0.21 (-3.88%)
Nov 20, 2024, 4:00 PM EST - Market closed
Molecular Partners AG Revenue
Molecular Partners AG had revenue of 681.00K CHF in the quarter ending September 30, 2024, a decrease of -73.20%. This brings the company's revenue in the last twelve months to 6.00M, down -31.03% year-over-year. In the year 2023, Molecular Partners AG had annual revenue of 7.04M, down -96.29%.
Revenue (ttm)
6.00M CHF
Revenue Growth
-31.03%
P/S Ratio
n/a
Revenue / Employee
35,833 CHF
Employees
168
Market Cap
199.84M USD
Revenue Chart
* This company reports financials in CHF.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 7.04M | -182.56M | -96.29% |
Dec 31, 2022 | 189.60M | 179.85M | 1,843.82% |
Dec 31, 2021 | 9.75M | 410.00K | 4.39% |
Dec 31, 2020 | 9.34M | -11.04M | -54.16% |
Dec 31, 2019 | 20.38M | 10.03M | 96.84% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Amarin Corporation | 241.02M |
Editas Medicine | 61.76M |
Orchestra BioMed Holdings | 2.65M |
Quantum-Si incorporated | 2.27M |
Inhibrx Biosciences | 1.57M |
MOLN News
- 13 days ago - Molecular Partners Presents Preclinical Proof-of-Concept for CD3 Switch-DARPin T Cell Engager, Clinical Biomarker Analyses for MP0317 at SITC 2024 - GlobeNewsWire
- 20 days ago - Molecular Partners Q3 2024 Interim Management Statement: Multiple Updates Across Portfolio, Radio-DARPin candidate MP0712 preparing for clinical entry, MP0533 Phase 1 on-going - GlobeNewsWire
- 27 days ago - Molecular Partners Announces Pricing of $20 Million Underwritten Offering - GlobeNewsWire
- 4 weeks ago - Molecular Partners and Orano Med Present Additional Positive Preclinical Data Supporting DLL3 Targeting Radio-DARPin Therapeutic Candidate MP0712 at EANM 2024 - GlobeNewsWire
- 4 weeks ago - Molecular Partners and Orano Med Strengthen Agreement to Co-Develop 212Pb-Based Radio-DARPin Therapeutics - GlobeNewsWire
- 6 weeks ago - Molecular Partners Announces upcoming poster presentations at the 2024 SITC Annual Meeting - GlobeNewsWire
- 7 weeks ago - Molecular Partners Announces Upcoming Top-Rated Oral Presentation on MP0712, a ²¹²Pb-labeled Radio-DARPin Therapeutic targeting DLL3 for Small Cell Lung Cancer co-developed with Orano Med, at EANM 2024 - GlobeNewsWire
- 3 months ago - Molecular Partners Reports H1 2024 Corporate Highlights and Financials - GlobeNewsWire